로딩 중…
지수 로딩 중…
KYUNG NAM PHARM.CO.,LTD.
053950· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,200-3.72%
2026-09-18
Financials
Valuation Metrics
KYUNG NAM PHARM.CO.,LTD.'s Market Cap is ₩432B. At end of 2025 it was ₩665B. Ranked #1870 of 2,421 in KR market (top 77%), #1155 of 1,640 on KOSDAQ (top 70%), #199 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 43.16B KRW | KR#1,870/2,421 Sec#199/231 |
| Revenue | 62.76B KRW | KR#1,676/2,421 Sec#111/231 |
| Net Income | -14.23B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 143.23B KRW | KR#1,542/2,421 Sec#118/231 |
| Net Assets | 117.50B KRW | KR#1,304/2,421 Sec#103/231 |
| Employees | 260 | KR#898/2,421 Sec#75/231 |
| Value | ||
| P/B | 0.37x | KR#488/2,421 Sec#16/231 |
| P/S | 0.69x | KR#1,131/2,421 Sec#57/231 |
| FCF Yield | -6.80% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -12.11% | KR#1,976/2,421 Sec#149/231 |
| ROA | -9.94% | KR#2,100/2,421 Sec#158/231 |
| Op. Margin | -1.33% | KR#1,706/2,421 Sec#115/231 |
| Revenue Growth | 14.33% | KR#717/2,421 Sec#70/231 |
| Financial Health | ||
| Debt Ratio | 21.90% | KR#414/2,421 Sec#51/231 |
| Total Debt | 5.16B KRW | KR#1,777/2,421 Sec#168/231 |
| FCF | -2.93B KRW | KR#1,386/2,421 Sec#107/231 |
| Cash | 18.40B KRW | KR#1,295/2,421 Sec#98/231 |
| Current Ratio | 2.77x | KR#613/2,421 Sec#80/231 |
| Performance | ||
| 1Y Return | -28.69% | KR#1,526/2,421 Sec#121/231 |
| 1M Return | 40.49% | KR#78/2,421 Sec#8/231 |
| From 52W High | -60.57% | KR#1,881/2,421 Sec#145/231 |
| 1Y MDD | -70.26% | KR#1,996/2,421 Sec#172/231 |
| Trading | ||
| Volume | 205,579 shares | KR#478/2,421 Sec#30/231 |
| Trading Value | 450.7M KRW | KR#962/2,421 Sec#96/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | -725 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,989 KRW | KR#1,359/2,421 Sec#96/231 |
Company Info
Kyungnam Pharm, established in 1998 and listed on KOSDAQ in 2001, adopted its current name after merging with HS Biopharm in 2010. The company manufactures and sells pharmaceuticals and health functional foods, distributing flagship products like Lemona nationwide through pharmacies and large supermarkets. It is expanding its business beyond its OTC specialist image, diversifying and growing the Lemona product line to increase sales and customer engagement through enhanced online marketing.